361 related articles for article (PubMed ID: 24375059)
1. The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.
Hompes D; D'Hoore A; Wolthuis A; Fieuws S; Mirck B; Bruin S; Verwaal V
J Surg Oncol; 2014 May; 109(6):527-32. PubMed ID: 24375059
[TBL] [Abstract][Full Text] [Related]
2. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
[TBL] [Abstract][Full Text] [Related]
3. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J
Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983
[TBL] [Abstract][Full Text] [Related]
4. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R
J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304
[TBL] [Abstract][Full Text] [Related]
5. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
Glockzin G; von Breitenbuch P; Schlitt HJ; Piso P
J Surg Oncol; 2013 May; 107(6):574-8. PubMed ID: 22833286
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis.
Leung V; Huo YR; Liauw W; Morris DL
Eur J Surg Oncol; 2017 Jan; 43(1):144-149. PubMed ID: 27780675
[TBL] [Abstract][Full Text] [Related]
7. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
[TBL] [Abstract][Full Text] [Related]
8. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer.
Gervais MK; Dubé P; McConnell Y; Drolet P; Mitchell A; Sideris L
J Surg Oncol; 2013 Dec; 108(7):438-43. PubMed ID: 24018983
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: higher complication rate for oxaliplatin compared to Mitomycin C.
Rouers A; Laurent S; Detroz B; Meurisse M
Acta Chir Belg; 2006; 106(3):302-6. PubMed ID: 16910003
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study.
Bakkers C; van Erning FN; Rovers KP; Nienhuijs SW; Burger JW; Lemmens VE; Aalbers AG; Kok NF; Boerma D; Brandt AR; Hemmer PH; van Grevenstein WM; de Reuver PR; Tanis PJ; Tuynman JB; de Hingh IH
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1902-1907. PubMed ID: 32340819
[TBL] [Abstract][Full Text] [Related]
13. A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C.
Votanopoulos K; Ihemelandu C; Shen P; Stewart J; Russell G; Levine EA
J Surg Res; 2013 Jan; 179(1):e133-9. PubMed ID: 22480844
[TBL] [Abstract][Full Text] [Related]
14. Mitomycin C Pharmacokinetics as Predictor of Severe Neutropenia in Hyperthermic Intraperitoneal Therapy.
Kemmel V; Mercoli HA; Meyer N; Brumaru D; Romain B; Lessinger JM; Brigand C
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S873-9. PubMed ID: 26100819
[TBL] [Abstract][Full Text] [Related]
15. HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy.
McConnell YJ; Mack LA; Francis WP; Ho T; Temple WJ
J Surg Oncol; 2013 May; 107(6):591-6. PubMed ID: 23129533
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from appendix: preliminary results of a survival analysis.
Marcotte E; Sideris L; Drolet P; Mitchell A; Frenette S; Leblanc G; Leclerc YE; Dubé P
Ann Surg Oncol; 2008 Oct; 15(10):2701-8. PubMed ID: 18654822
[TBL] [Abstract][Full Text] [Related]
17. Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix.
Sideris L; Mitchell A; Drolet P; Leblanc G; Leclerc YE; Dubé P
Can J Surg; 2009 Apr; 52(2):135-41. PubMed ID: 19399209
[TBL] [Abstract][Full Text] [Related]
18. 120 peritoneal carcinomatoses from colorectal cancer treated with peritonectomy and intra-abdominal chemohyperthermia: a S.I.T.I.L.O. multicentric study.
Cavaliere F; Valle M; De Simone M; Deraco M; Rossi CR; Di Filippo F; Verzi S; Giannarelli D; Perri P; Pilati PL; Vaira M; Di Filippo S; Garofalo A
In Vivo; 2006; 20(6A):747-50. PubMed ID: 17203760
[TBL] [Abstract][Full Text] [Related]
19. Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience.
Scaringi S; Kianmanesh R; Sabate JM; Facchiano E; Jouet P; Coffin B; Parmentier G; Hay JM; Flamant Y; Msika S
Eur J Surg Oncol; 2008 Nov; 34(11):1246-52. PubMed ID: 18222622
[TBL] [Abstract][Full Text] [Related]
20. Survival prognostic factors in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy: a single institution experience.
Nikolic S; Dzodic R; Zegarac M; Djurisic I; Gavrilovic D; Vojinovic V; Kocic M; Santrac N; Radlovic P; Radosavljevic D; Pupic G; Martinovic A
J BUON; 2014; 19(1):66-74. PubMed ID: 24659645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]